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Antibodies that activate p2 integrins can generate 
different ligand binding states
A human erythroleukemic cell line (K562) that does not normally express (32 
integrins has been transfected with the genes encoding these integrins. The 
resulting cell lines show minimal background adhesion but can be stimulated to 
bind to appropriate substrates when activated with either of two different 
antibodies to CD18. The two antibodies appear to generate different ligand 
binding states in LFA-1 such that different members of the ICAM family are 
recognized. Antibody-activated complement receptor type 3 and p150,95- 
transfected cells bind protein-coated surfaces, although they require slightly 
different activation conditions for optimal binding.
1 Introduction
The interaction of the (32 family of integrins with their 
ligands is known to play a crucial role in the effective 
functioning of the immune system. This is highlighted by a 
genetic deficiency disease termed leukocyte adhesion defi­
ciency (LAD) in which patients, unable to express func­
tional (52 integrins, frequently fall victim to devastating 
infections (reviewed in [1]). Whilst cell adhesion is vital for 
immune function, it is also critically important that adhe­
sive interactions in the immune system are tightly regu­
lated , since the inappropriate activation of immune cells, as 
for example in autoimmune disease, can lead to massive 
destruction of surrounding tissues. (32 integrins have a very 
limited tissue distribution, showing differentiation stage- 
specific expression on leukocytes [2]. Their functional 
interactions are regulated at a number of different levels. 
For example, CR3 and pl50,95 ((32 family members 
expressed predominantly on myelomonocytic cells) are 
stored in intracellular granules that are mobilized to the cell 
surface only following cellular activation [3-5]. Over the 
last few years, it has become increasingly clear that cells are 
also capable of controlling the affinity/avidity of integrins 
for their ligands [6-9]. Thus, cross-linking of the T cell 
receptor has been shown to increase LFA-l-mediated 
adhesion without increasing surface expression of this 
molecule [10, 11].The mechanisms by which this regulation 
is achieved are not understood but may involve conforma­
tional changes in the integrin which alter its ability to 
interact with ligands. Integrin activation can be induced 
experimentally with a variety of agents that activate 
intracellular signalling pathways. Recently, there has been 
increasing interest in a set of monoclonal antibodies that 
appear to bind to the extracellular portion of integrins and 
stimulate conformational changes which lead to increased 
ligand binding [12-21]. These changes may mimic those 
brought about by normal intracellular signals.
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Here we report the effects of two antibodies that bind to 
CD18 and stimulate adhesion of K562 cells transfected with 
(32 integrins. These antibodies can stimulate adhesive 
interactions for all three of the transfected integrins and 
generate different states in LFA-1 which show different 
ligand binding characteristics.
2 Materials and methods
2.1 Cloning and vector construction
The CD 18, CD lib , and CD 11c genes were cloned by PCR 
amplification from first strand cDNA prepared from U937 
cells stimulated with PMA for 48 h} then subcloned into a 
derivative of the expression vector EE6I1CMV [22] carrying 
a G418-resistance marker for expression in K562 cells. The 
C D lla gene was obtained from T. Springer, the ICAM-1 
gene from B. Seed, and the ICAM-3 and VCAM-1 genes 
from D. Simmons. The five extracellular domains of ICAM- 
1, ICAM-3 and the four extracellular domains of VCAM 
were fused in-frame with human IgGl heavy chain constant 
region to generate fusion proteins termed ICAM-lFc, 
ICAM-3Fc and VCAM-Fc, respectively. The gene encoding 
the ICAM-2Fc fusion protein was obtained from D. Sim­
mons [23]. TheVCAM-Fc and ail three ICAM-Fc fragments 
were subcloned into EE12 (a derivative of EE6I1CMV 
containing the GS expression cassette from pSV2GS [24]), 
for expression in either COS-1 or CHOL761h cells [25],
2.2 Cell culture
The JY human B lymph oblast oid cell line [26] was a gift 
from Dr. R. Rothlein and the human erythroleukemic cell 
line K562 was obtained from the European Collection of 
Animal Cell Cultures (No. 891214 07). Both cell lines were 
maintained in DMEM (GIBCO BRL, Paisley, Scotland) 
supplemented with 10 % FCS. K562 cells were transfected 
using the Bio-Rad gene pulser unit (Bio-Rad, Hemel 
Hempstead, GB). Cells (1 X 107) were transfected with 
40 \ig of linearized CD 11 and CD 18 plasmid DNA. Cells 
and DNA were subjected to one pulse of 450 V at a 
capacitance of 960 jaF, and transfectants were selected in 
either 0.5 or 1 mg/ml G418 (GIBCO BRL).
COS-1 cells were transfected as described by Whittle et al. 
[27]. CHOL761h cells were transfected as described by
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Gorman et aL [28]. Stable transfected cell lines were 
maintained in GMEM-S medium [29] with 20 jxM methio­
nine sulfoximine (Sigma, Poole, GB).
2.3 Monoclonal antibodies
mAb MOPC21 [30] (mouse IgGl) and UPC10 (mouse 
IgG2a) (Sigma) were used as non cell-binding controls. 
DA36 (mouse IgGl) binds to human LFA-1 and blocks 
LFA-l-mediated aggregation events [12]. KIM 249 (mouse 
IgGl) binds to human CR3 and blocks CR3-mediated 
adhesion events (M. K. Robinson, unpublished observa­
tions). Antibody 6.5E (mouse IgGl) directed against CD18 
blocks both LFA-1- and CR3-mediated adhesion events 
[12]. KIM 127 and KIM 185 (both mouse IgGl) antibodies 
are directed against CD18 [12 and 19]. Antibody 3.9 
(mouse IgGl) binds human pl50,95 [31] and mAb 24 
(mouse IgGl) binds all three CD11 subunits [32]. NKI-L16 
is a mouse IgG2a directed against LFA-1 [16].
2.4 FACS analysis
Cells were stained with 20 ¡u-g/ml of purified antibody or an 
appropriate dilution of NK1-L16 tissue culture supernatant 
in PBS containing 5% normal rabbit serum and 0.01% 
sodium azide (PBA) for 40 min at the temperature indi­
cated in the legend toTkble 1. Cells were then washed twice 
in PBA followed by incubation for 40 min with a phyco- 
erytbrin-labeled goat anti-mouse immunoglobulin (Stra- 
tech Scientific, Luton, GB) diluted in PBA. Analysis was 
performed on a FACScan machine (Becton Dickinson, San 
Jose, CA), with the aid of the Consort 30 and Lysys software 
packages.
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2*5 Cell adhesion assays
2.5.1 Binding of transfected K562 cells to BSA
A  96-well Immuno-plate (Nunc Inc., Naperville IL) was 
coated with 10 % BSA (Fraction V, Sigma) in PBS and 
incubated at room temperature for 1 h. Plates were washed 
three times in PBS before addition of 5 x 104 cells/well in 
DMEM containing 10 % FCS. PM A (final concentration of 
100 ng/ml) or antibodies KIM 127 or KIM 185 (final con­
centration 25 (ig/ml) were added to stimulate adhesion. 
Plates were incubated at 37 °C for 30 min before being 
washed in DMEM containing 10 % FCS. After washing, 
100 [d/well of DMEM containing 10 % FCS was added 
followed by 20 \il of 5 mg/ml 3-[4,5-dimethylthiazol~2- 
yl]-2,5-diphenyltetrazolium bromide (MTT; Sigma). Plates 
were incubated at 37 °C for 3 h and the resulting tetrazolium 
crystals were disolved by the addition of 0.04 N HC1 in 
isopropanol [33]. Plates were read on a ELISA reader, 
using a test wavelength of 570 nm and a reference wave­
length of 630 nm.
2.5.2 Binding of JY and transfected K562 cells to 
ICAM-Fc
A  96-well Nunc Immuno-plate was coated overnight at 4 °C 
with 2 |xg/mL of a goat anti-human Fc (Jackson 109-
006-098). Plates were blocked with 1% BSA in PBS 
incubated at room temperature for 1 h. COS or CHO cell 
supernatant containing the ICAM-Fc was added at the 
concentration (determined by measuring immunoglobulin 
Fc concentration by ELISA) stated in the figure legends 
and incubated for 1 h at room temperature. Plates were 
washed three times in PBS and the addition of cells and the 
rest of the assay were then carried out as described above. 
Antibody additions were made as described in the figure 
legends. For cell binding in the presence of Mn2+ alone, the 
assay was carried out essentially as described above, except 
that after incubation with the ICAM-Fc, plates were 
washed in Ca2+, Mg2+-free HBSS containing 10 m M  
EDTA, and twice in Ca2h, Mg2+-free HBSS. Before 
addition to the plate, the cells were also washed twice in 
Ca2+, Mg2+-free HBSS containing 10 m M  EDTA and twice 
in Ca2+, Mg2+ free HBSS. The adhesion assay and subse­
quent incubation with MTT were carried out in serum-free 
HBSS with the divalent cation additions shown. All 
antibodies used were dialyzed into Ca2+, Mg2+-free PBS 
and dilutions were made in Ca2+, Mg2+~free HBSS. A stock 
solution of 100 m M  MnCla was made up in Ca2+, Mg2+-free 
HBSS pH 7.4, and all dilutions were made in Ca2+, 
Mg2+-free HBSS.
2.6 Statistical analysis of results
Where appropriate, data were analyzed using S tat graphics 
version 4 (Statistical Graphics Corporation, Rockville, 
MD). Analysis of variance was performed to detect differ­
ences between groups. If a difference was found, then a 
two-tailed ¿-test was performed.
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3 Results
3.1 Characterization of transfected K562 cell lines
The human erythroleukemic cell line K562 does not 
normally express CD 18 [34] (Table 1). However, when the 
cells were stably transfected with cDNA encoding CD 18 
(P2 subunit) and one of the three a subunits that can pair 
with CD 18, (CD 11a, CD 11b or CD 11c), surface expression 
of the appropriate integrin was readily detected (Table 1). 
In no case was there any evidence of K562 cells expressing 
any a-chain from the (32 integrin family apart from the one 
encoded by the transfected gene (Table l).The transfected 
(32 integrins expressed in K562 cells appeared to be in a low 
state of activation, as judged by their low, unstimulated 
binding to ligands (Fig. 1 and 2) and their low-level binding 
of mAb NK1-L16 and 24 (Table 1). These antibodies have 
previously been shown to recognize activation epitopes [35 
and 36]. It is not clear why the anti-CD 18 antibodies (6.5E, 
KIM 127 and KIM 185) all show lower levels of staining 
than the anti-cc-chain antibodies (DA36, KIM249 and 
mAb 3.9).This may merely reflect affinity differences, but 
it is possible that all of these three anti-CD18 antibodies 
only recognize subsets of the CD18-containing integrins on 
the cell surface. It is unlikely that this observation indicates 
substantial unpaired a-sub unit surface expression since at 
least for CD 11a and CD 11c unpaired molecules have been 
shown to be inefficiently transported to the cell surface 
([37], and S. Ortlepp, unpublished observations).
Table 1. Antibody binding to transfected K562 cellsa)
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MOPC21
(control)
UPC 10 
(control)
DA 36 
(CD 11a)
KIM 249 
(CD lib )
AB 3.9 
(CDllc)
NK1-L16 
(CD 11a)
AB 24 
(all a 
subunits)
6.5E 
( CD 18)
KIM 127 
(CD 18)
KIM 185 
(CD18)
K562 9.7 10.1 11.4 11.8 30.3 7.5 10.3 10.3 14.0 8.8
KL/4
(LFA-1)
5.7 5.7 1256.6 10.6 19.7 70.9 31.3 823.8 245.4 499.4
KC/16
(CR3)
6.8 8.5 13.1 724.5 24.3 9.1 23.01 622.8 122.6 174.9
P/5
(150,95)
7.6 9.9 11.7 10.9 754.9 8.6 60.3 503.5 233.9 401.5
a) FACS analysis of K562 cells and the LFA-1 (KL/4), CR3 (KC/16), and pl50,95 (p/5) -transfected K562 cells stained with anti-(32 
integrin antibodies. Antibodies were used at a concentration of 20 \xgim\ and staining for first and second stage antibodies was done at 
4°C except for staining with KIM 127 and AB24, which was done at 37 °C for both stages. Results are shown as mean 
fluorescence.
«
3 .2  Stimulated ligand binding by K562 cells
Short-term treatment with PM A alone was not sufficient to 
cause increased ligand binding by the (32 integrins on the 
transfected K562 cells (Fig. 1). However, the cells could be 
stimulated to bind to appropriately coated plates when 
incubated with the monoclonal antibodies KIM 127 or 
KIM 185 (Figs. 1 and 2); these antibodies have previously 
been shown to activate (32 integrin function [12, 19]. As can 
be seen in Fig. 1, cells expressing either pl50>95 or CR3, 
bound to BSA-coated plastic in a (32 integrin-dependent 
manner when stimulated with KIM 185. KIM 127 was able 
to  stimulate pl50,95 binding to protein-coated plastic, but 
did not stimulate the binding of the CR3-transfected cells 
when used alone. Table 1 clearly shows that the KIM 127 
epitope is expressed by the CR3~transfected cells, and we 
have previously reported that KIM 127 is able to activate 
CR3 expressed on human PMN to bind to protein-coated 
plastic [12]. The binding of KIM 127 to CR3-transfected 
K562 cells can mediate ligand binding, but only in combi­
nation with PMA (under conditions when neither PMA nor
KIM 127 alone stimulate binding) (Fig. lb). PMA treat­
ment also enhances the increase in ligand binding caused by 
KIM 185 alone.
As expected, the LFA-l-transfected cells did not bind to 
BSA-coated plastic (Fig. lc) but did bind to an ICAM- 
lFc-coated plate (Fig. 2). This is consistent with previous 
reports that both pl50,95 and CR3 can bind to denatured 
protein [38] and that LFA-1 binds to members of the ICAM 
family [39-41].
3.3 KIM 127 and KIM 185 generate different ligand 
binding states in LFA-l-transfected cells
An earlier observation that KIM 185-mediated aggregation 
of JY cells could be almost completely blocked by anti- 
ICAM-1 antibodies, but that KIM 127-mediated aggrega­
tion of JY cells was only slightly inhibited by anti-ICAM-1 
antibodies (D. Andrew, unpublished observation), led us to 
explore the binding of LFA-lntransfected K562 cells to
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Figure 1. Binding of transfected K562 cells to BSA-coated plastic, (a) Binding of pl50,95-transfected cells, (b) binding of 
CR3-transfected cells and (c), binding of LFA-l-transfected cells. Blocking antibodies DA36, KIM249 and Ab3,9 were used at a 
concentration of 20 |Ag/ml. The degree of binding was assessed as absorbance at 570 nm using the MTTassay (Sect. 2.5.1). Shaded bars 
represent experiments in the presence of control antibody MOPC21, and striped bars, experiments in the presence of Ab3.9 ( la ) , KIM 249 
( lb ) ,  or DA36 (lc). Cells were stimulated using the treatments shown below the figure. Antibodies were used at 25 [xg/ml and PMA at 
100 ng/ml. * Indicates treatments causing significantly more binding than seen with unstimulated cells (p <  0.01). The data represent two 
independently performed experiments.
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Figure 2. Binding of LFA-l-transfected K562 cells to immuno­
globulin fusion proteins, (a) binding to ICAM-lFc, (b) binding to 
VCAM-lFc. Blocking antibody DA36 and control antibody 
MOPC21 were used at a concentration of 20 [Ag/ml, and 100 [¿1/well 
of the fusion proteins (from COS cell supernatant) were coated at a 
concentration of 0.25 \iglm\ as assessed by IgG ELISA. Shaded 
bars represent experiments in the presence of control antibody 
MOPC21, and striped bars experiments in the presence of DA36. 
Cells were stimulated using the treatments shown below the figure. 
Antibodies were used at 25 [Xg/ml and PMA at 100 ng/ml. ♦Indi­
cates treatments causing significantly more binding than seen with 
unstimulated cells, (p  <  0.001).The data presented here represent 
two independently performed experiments.
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Figure 3. Binding of LFA-l-transfected K562 cells to ICAM-3 
immunoglobulin fusion proteins. Blocking antibody DA36 and 
control antibody MOPC21 were used at a concentration of 
20 ng/ml, and the ICAM-3 fusion protein (from transfected CHO 
cell supernatant) was coated 100 fig/well at a concentration of 
0.25 ^ig/ml as assessed by IgG ELISA. Shaded bars represent 
experiments in the presence of control antibody MOPC21, and 
striped bars experiments in the presence of DA36. Cells were 
stimulated using the treatments shown below the figure. Antibod­
ies were used at 25 x^g/ml and PMA at 100 ng/ml. * Indicates 
treatments causing significantly more binding than seen with 
unstimulated cells (p <  0.001).The data presented here represent 
two independently performed experiments.
0.4-t
E
5  o*3O
4»
t)OcA
O
t t
<
0,2 -
0.1 -
T
| l |  
mb
-M
V* rv'A 6
T
mZ: %
m
m i0 , 0  1 1 I  ■ f i p i i i ' i l , K S f  
0  0 . 0 0 1  0 . 0 1
•V . ;
/ /  a - . : \
4
If
I ,  ™ i | - n  - ,
0.1 0.5 1
Mn++ mM
Figure 4 .  Binding of LFA-l-transfected K562 cells to 5-domain 
ICAM-3 Fc in the presence of Mn2+ ions. Key: black: no 
stimulation, dark bars: PMA, gray: KIM 127, light bars: 
KIM 185.
different members of the ICAM family. As can be seen in 
Fig. 2a, KIM 127 and KIM 185 both stimulated the LFA- 
l-transfected cells to bind to a plate coated with ICAM-lFc 
containing all five extracellular domains of ICAM4. This 
binding was inhibited by an anti-LFA-1 antibody, and no 
.binding was seen to the control VCAM-Fc. Fig. 3 shows 
that KIM 127 also stimulated the binding of the LFA- 
l-transfected cells to a plate coated with an ICAM-3Fc 
containing all five extracellular domains of ICAM-3; this 
binding was blocked by an anti-LFA-1 antibody. Unlike 
KIM 127, KIM 185 did not stimulate any increase in 
ICAM-3 binding. This obervation was unlikely to be due to 
steric hindrance between ICAM-3 and KIM 185, since a 
combination of KIM 185 and elevated concentrations of 
manganese (from 10 jo,M) did lead to the LFA-l-transfected 
cells binding to ICAM-3 (Fig. 4), although neither agent 
alone was sufficient to stimulate this binding (Figs. 3 
and 4).
Fig. 5 shows a titration of KIM 127 and KIM 185 in assays of 
binding of the LFA-l-transfected K562 cells to either 
ICAM-1 or ICAM-3. KIM 127 and KIM 185 were approxi­
mately equipotent in activating binding to ICAM-1 
(Fig. 5a). Activation of LFA-1 binding to ICAM-3 required 
significantly higher concentrations of KIM 127 than binding 
to ICAM-1. KIM 185 did not stimulate binding to ICAM-3 
even when added at 100 i^g/ml.
3.4 Neither KIM 127 nor KIM 185 stimulate ICAM-2 
binding
ICAM-2 has only two extracellular domains [42] and 
neither KIM 127 nor KIM 185 stimulated any increase in 
binding to a plate coated with ICAM-2Fc (data not shown). 
To date, we have not found conditions that stimulate the 
LFA-1 transfected K562 cells to bind to ICAM-2, although
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Figure 5. Antibody-stimulated binding of LFA-l-transfected 
K562 cells to ICAM-1 (a) and ICAM-3 (b).The box indicates the 
background level of binding in the absence of antibody. Key: 
•  KIM 127, 4  KIM 185.
the B lymphoblastoid cell line JY will bind in an LFA- 
l-dep£ndent manner when stimulated with PMA (Fig. 6), 
indicating that the ICAM-2 fusion protein is functional.
4 Discussion
«
The human erythroleukemic cell line K562 has been 
independently transfected with both chains of all three of 
the (32 integrins, and different lines showed good levels of 
surface expression of all three integrins. These adhesion 
molecules seemed to be in a low state of activation as 
judged by the low-level binding to immobilized ligands, and 
low binding of antibodies reported to recognize activation 
epitopes. Short-term treatment of the cells with PMA was 
not sufficient to increase |32-mediated adhesion of these 
transfected cells. Similar observations were made when the 
a  chain of VLA-2 was transfected into K562 cells [43]. 
However, the ability of integrins in K562 cells to respond to 
PMA appears to be molecule specific, since cells expressing 
a6 have been reported to show increased ligand binding 
following PMA treatment [44]*
The (32 integrin-transfected K562 cells could be activated to 
bind ligands by incubation with antibodies against CD 18 
that have previously been shown to stimulate adhesive 
interactions. Antibody activation of K562 cells transfected
1.0-
£§ 0.8- 
ui
0-6 -o c(B
•e 0.4 •o «
S k
< 0.2- 
I
0 . 0 - , -------------------------------------------------------, ----------
NO STIM PMA
Figured. Binding of JY cells to ICAM-2 Fc fusion protein. 
Antibodies MOPC21 and DA36 were used at a concentration of
20 fjig/ml. ICAM-2Fc (from COS cell supernatant) was coated at a 
concentration of 0.25 M g/m l, as assessed by IgG ELISA. Shaded 
bars represent experiments in the presence of control antibody 
MOPC21, and striped bars experiments in the presence of DA36. 
Cells were stimulated with PMA at a concentration of 100 ng/ml. 
* Indicates treatments causing significantly more binding than seen 
with unstimulated cells, (p <  0.001).
with either CR3 or pl50,95 led to binding to protein-coated 
plastic. These cells appeared to recognize a variety of 
proteins bound to the plastic equally well, including BSA, 
ICAM-Ig fusions, control Ig fusions and serum proteins 
(data not shown). This can be explained, if, as has been 
suggested, CR3 and pl50,95 are able to bind epitopes on 
denatured proteins [38]. Interestingly, although both 
pl50,95 and CR3 are generally considered to have similar 
ligand-binding chacteristics, a difference is seen in the 
ability of KIM 127 to activate the two molecules. KIM 127 
stimulates p'150,95 binding alone, while it will only stimu­
late CR3 binding in combination with PMA. This may 
indicate that although the two adhesion molecules bind to 
similaiTigands, their activation is independently controlled. 
We have previously reported that KIM 127 can activate 
CR3 on human PMN to bind to protein-coated plastic [12], 
suggesting that CR3 expressed on PMN is in a different 
activation state from that expressed by transfected K562 
cells. PMA treatment of the K562 transfectants may move 
the CR3 further along the activation pathway, allowing 
KIM 127 binding to move the molecule into a ligand- 
binding conformation. KIM 185 stimulated both CR3- and 
pl50,95-mediated adhesion in the absence of PMA, 
although CR3 adhesion is further enhanced in the presence 
of PMA.
It has been proposed that the affinity change associated 
with LFA-1 activation is not a simple on/off switch, but a 
more complex series of changes with at least three detect­
able conformational states [45], In the case of some 
integrins, different activation states can lead to different 
patterns of ligand binding [46 and 47], The data presented 
here with the LFA-l-transfected K562 cells suggests that 
different activation states of LFA-1 may also have impor­
tant functional consequences with regard to interaction 
with different members of the ICAM family. KIM 127 
binding generates a conformation of LFA-1 which binds
both ICAM-1 and ICAM-3, but not ICAM-2; while 
KIM 185 binding causes a conformation which only binds 
ICAM-1 .These differences are unlikely to be due merely to 
different degrees of steric hindrance, since KIM 185 can 
stimulate binding to ICAM-3 when non-physiological man­
ganese concentrations are used. Although ICAM-1 and
ICAM-3 share extensive homology, it is interesting to note 
that domain one, which, for ICAM-1, contains critical 
elements for LFA-1 binding, shows less sequence conser­
vation than some of the other domains [48]. Landis et al. 
[49] have reported that some anti-LFA-1 antibodies are 
able to block binding to ICAM-3 > but not to ICAM-1. This 
again supports the idea that LFA-1 interacts in distinct ways 
with these two ligands.
From what is known of the tissue distribution and expres­
sion kinetics of the different ICAM family members, it is 
clear that there may be advantages in inflammatory cells 
being able to increase binding to some forms of ICAM but 
not others. For example, ICAM-1 expression is induced by 
inflammatory stimuli, but ICAM-2 and -3 [21, 36 and 39] 
are expressed constitutively. In an inflammatory setting, it 
may be advantageous for the immune system to focus 
activated LFA-1-bearing cells at the inflammed site, but not 
allow them to interact with constitutively-expressed forms 
of ICAM on other, non-involved tissues. It is also known 
that LFA-1 binding to ICAM can lead to intracellular 
signaling [49-53]. It will be interesting to determine 
whether the signals generated by LFA-1 interacting with 
different ICAM forms has different functional conse­
quences. This would further support the importance of the 
need to control interactions with different members of the 
ICAM family.
The data presented here are consistent with a model in 
which integrins can exist in multiple activation states, 
some, but not all of which are able to bind ligand. Many of 
these ligand-binding states would be able to bind only to a 
subset of the full range of potential ligands.
Even integrin activation states incapable of counterrecep­
tor binding may have an important regulatory role, since 
different integrin states may respond differently to inflam­
matory stimuli. This view is supported by recent observa­
tions by Binnerts et al. [54], who showed that in a T cell 
clone, KIM 127 and KIM 185 could stimulate patterns of 
LFA-l-dependent binding different from those reported 
here. The different binding patterns may be due to 
differences in the starting activation states of the LFA-1 
molecules in the various cell lines.
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